Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Supplementary Figure 5. Growth inhibition by BBT-176 with and without cetuximab in BBT-176-resistant clones. IC50 values were measured 3 days later and cell growth was plotted relative to untreated control cells (mean ± SD). Abbreviation: BR(1/2), BBT-176-resistant (clone 1/2).